Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Cosmetology Market to reach USD 239.24 Bn dominated by Facial Contouring and…
Get your Sample PDF:https://www.stellarmr.com/report/req_sample/Cosmetology-Market/2077 Get your Sample PDF: https://www.stellarmr.com/report/req_sample/Cosmetology-Market/2077 Key Highlights of the Report L'Oréal ( France ):Major Playerin Cosmetology Industry L'Oréal is known for investing heavily in advertising and research to maintain its leadership. In 2023, the company spent about13.36 billion Euroson advertising to ensure its brands like Lancôme, Essie, and...
PR Newswire
22/07/2024
Q'Apel Medical Announces Leadership Transition
"Jodie has been an integral part of Q'Apel's leadership team for the past three years as Chief Marketing Officer and General Manager of International. We are thrilled to have her lead the organization going forward," commented Mr. Nelson. "With a deep industry knowledge and expertise bringing disruptive technologies to market, Jodie is ideally suited to spearhead this next phase of the company's growth. I am confident that under her leadership, the organization will deliver on its…
PR Newswire
22/07/2024
Digital X-ray Systems Market to be Worth $14.33 Billion by 2031 - Exclusive…
Digital X-ray is an advanced form of X-ray where a digital radiographic image is produced directly on a computer. The X-ray sensitive plate is used to capture the data during the examination of patients directly. These have high resolution and, hence, provide better and clearer images. The technological advancements in digital X-ray systems, such as AI-aided X-ray interpretation, tomosynthesis, dual-energy imaging, automatic image stitching, computer-aided diagnosis, and digital mobile…
PR Newswire
22/07/2024
CAR T-cell Therapy Market worth $29.0 billion by 2029 driven by Rising…
Browse in-depth TOC on "CAR T-cell Therapy Market" Browse in-depth TOC on "CAR T-cell Therapy Market" 281 - Tables 48 - Figures 276 - Pages GILEAD SCIENCES, INC. (US): Leader in CAR T-Cell Therapy Gilead Sciences, Inc. excels in biotechnology with a focus on innovative medicines for life-threatening diseases such as HIV, viral hepatitis, and cancer. The company is a key player in CAR T-cell therapy, offering FDA-approved products YESCARTA (Axicabtagene ciloleucel) and...
PR Newswire
22/07/2024
Luxury Furniture Market, valued at $24 Billion in 2024, Expected to Reach $41.1…
"The demand for luxury furniture is on the rise owning to shift in consumer preference and awareness of aesthetics and environment-friendly products for homes and offices. This trend is apparent most in home, office, hotel or restaurants, for instance, exclusive furniture and wooden flooring." " The demand for luxury furniture is on the rise owning to shift in consumer preference and awareness of aesthetics and environment-friendly products for homes and offices. This trend is…
PR Newswire
22/07/2024
Momcozy Launches Global Campaign to Support Diverse Breastfeeding Journeys This…
As part of the campaign, Momcozy will collaborate with Pumpspotting, a digital women's healthcare company delivering technology-driven solutions for moms, to embark on a 'Feel Better, Feed Better Tour' using a specially designed roving bus. This tour will visit key cities including Boston, New York City, Austin, Dallas, Washington D.C. and more, providing on-the-go support and guidance for nursing and pumping mothers. As part of the campaign, Momcozy will collaborate withPumpspotting, a...
PR Newswire
22/07/2024
YourBio Health Welcomes New Board Member, Mark Stevenson
"We enthusiastically welcome Mark Stevenson to YourBio Health's Board of Directors," said Paul Owen, President and CEO of YourBio Health. "Mark's deep experience optimizing strategy, innovation, and operations in complex, global life sciences business environments will be invaluable to YourBio Health as we grow our business and pursue our mission to improve the blood collection experience for patients." "We enthusiastically welcomeMark Stevensonto YourBio Health's Board…
PR Newswire
22/07/2024
Caidya Announces Leadership Transition: Barbara Lopez Kunz Named CEO
Dr. Lingshi Tan expressed his enthusiasm for Ms. Kunz's appointment, stating, "Barbara's leadership capabilities and profound understanding of the global healthcare landscape have been invaluable to our board. Her strategic vision and commitment to innovation have already significantly impacted our business. I have the utmost confidence in her ability to steer Caidya towards a successful future. I am thrilled she has accepted this expanded role and look forward to working closely with…
PR Newswire
22/07/2024
Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program
"Breast cancer is the most common cancer among women in Qatar, accounting for 32% of all female cancer cases[1]," said Dr. Sheikha Abu Sheikha, Director of Early Detection Programs at PHCC. "To address this, we're integrating Lunit's AI as a crucial second opinion for our radiologists. As the first country in the Middle East to implement AI across the entire screening program, we're reinforcing Qatar's commitment to high-quality healthcare for women across the country."…
PR Newswire
22/07/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 July 2024– On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the…
Nasdaq GlobeNewswire
22/07/2024
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and…
Jazz Investments I Limited (the "Issuer"), a subsidiary of Jazz Pharmaceuticals, today announced that it provided written notice to the exchange agent, the trustee and the holders of its 2.000% Exchangeable Senior Notes due 2026 (the "2026 notes") that it has irrevocably elected to fix the settlement method for exchanges of the 2026 notes to a combination of cash and ordinary shares of Jazz Pharmaceuticals with a specified cash amount per $1,000 principal amount of 2026 notes…
PR Newswire
22/07/2024
Medical & Commercial International (MCI) to Utilize GATC Health's AI Platform to…
"Clinical trial funding insurance is a revolutionary new insurance product with huge unmet demand, and access to Lloyd's will allow MCI to capitalize on this opportunity," said MCI CEO Phil Trafford. "Working side-by-side with lenders and investors, this new program will promote medical innovation and promises a level of risk assessment accuracy unparalleled in the industry." "Clinical trial funding insurance is a revolutionary new insurance product with huge unmet…
PR Newswire
22/07/2024
Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits…
BGM0504, an AI-assisted designed dual GIP and GLP-1 receptor agonist, demonstrates superior efficacy in both in vitro and in vivo experiments. Using AI-driven computer simulations, Bright Gene has discovered that optimal interaction between the glutamate residues on both GLP-1R and GIPR and the K20 residue of a peptide agonist provide superior activity. This interaction is a key insight not evident in cryo-EM studies. BGM0504 was designed to preserve the free amino group of the K20 residue by…
PR Newswire
22/07/2024
Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist…
1. GZR18 injection is an investigational drug and has not yet been approved in China. 1. GZR18 injection is an investigational drug and has not yet been approved inChina. 2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. The phase IIb clinical trial (CTR20231695) is a multi-center, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers inChina, recruiting a total of 340 participants. The...
PR Newswire
22/07/2024
Tilray Receives First New Cannabis Cultivation License in Germany Under New…
Tilray's Aphria RX Facility in Germany Granted New Cannabis Cultivation License, Allowing for ~5x Production Increase and New Strains to Enhance Patient Access Across the Country Aphria RX Designed with Guidance from Renowned Cannabis Grower of Broken Coast Cannabis NEUMÜNSTER, Germany, July22, 2024(GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in cannabis research, cultivation, production, and distribution, today announced that its...
Nasdaq GlobeNewswire
22/07/2024
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on…
MAINZ, Germany, July 22, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2024 on Monday, August 5, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please...
Nasdaq GlobeNewswire
22/07/2024
Grünenthal acquires US-company Valinor Pharma and becomes global owner of…
"As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio", says Gabriel Baertschi, CEO, Grünenthal. "The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal." "As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio", saysGabriel Baertschi, CEO…
PR Newswire
22/07/2024
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to…
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across EuropeLaunch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology 1, dermatology and rheumatologyCreates competition at earliest opportunity, enabling straightforward switching to broaden patient access and control costs in a growing market, with accessible indications currently...
Nasdaq GlobeNewswire
22/07/2024
Biosimilar Market to Surpass $102.68 Billion by 2034 with 8.9% Annual Growth…
Global demand for biosimilars is rising as healthcare systems seek cost-effective alternatives to expensive biologic medications. These highly similar biologics are gaining popularity worldwide due to their equivalent efficacy, safety, and affordability. The anticipated growth in the biosimilar market in the coming years will be driven by the expiration of patents on blockbuster biologics and the imperative to reduce healthcare expenditures. Global demand for biosimilars is rising as…
PR Newswire
22/07/2024
Buyback of Class B shares in Essity during week 29, 2024
The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. The share repurchase is financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Class B shares in Essity were repurchased as follows: All purchases...
PR Newswire
22/07/2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for…
“ZW191 is a differentiated product candidate in our pipeline that reflects the strength of our approach in developing best-in-class antibody-drug conjugates,” said Paul Moore, Chief Scientific Officer of Zymeworks. “Developed to target FR⍺, which is expressed in several types of difficult-to-treat cancers, ZW191 incorporates a novel antibody and drug-linker that provide a unique combination of antibody-linker stability and payload potency, together with strong bystander activity, which...
Nasdaq GlobeNewswire
22/07/2024
JPA Health Expands Global Presence with Acquisition of Award-Winning akt health…
Founded in 2018 by Anna Radnavale, Katy Foy and Tim Cockroft, akt health offers a bespoke service to healthcare clients, motivated by a central mission to make the world a healthier place while improving and protecting lives. The team has received global recognition for their work across Diversity & Inclusion Communications, Healthcare PR, Digital and Multichannel Communications. Founded in 2018 by Anna Radnavale,Katy FoyandTim Cockroft, akt health offers a bespoke service to healthcare...
PR Newswire
22/07/2024
SIFI Receives COMP Positive Opinion on Orphan Drug Designation for Polihexanide…
Polihexanide received an ODD in fungal keratitis from the US Food and Drug Administration (FDA) in February 2022. Polihexanide received an ODD in fungal keratitis from the US Food and Drug Administration (FDA) inFebruary 2022. Fungal keratitis, a severe infection of the cornea caused by fungi such as Fusarium, Aspergillus, and Candida species, is a significant cause of ocular morbidity and unilateral blindness worldwide 1. Although rare, this condition can lead to substantial vision loss...
PR Newswire
22/07/2024
Addex's Partner Discontinues ADX71149 development in Epilepsy
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy...
Nasdaq GlobeNewswire
22/07/2024
Altri Comunicati
